Brought to you by 
DxS works with BI on companion test for cancer candidate
22 Oct 2013
Executive Summary
In collaboration with Boehringer Ingelheim, DxS (personalized oncology medicine) will adapt its TheraScreen EGFR mutation kit to develop a companion diagnostic for BI's non small-cell lung cancer compound Tovok (BIBW2992).
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
DxS works with BI on companion test for cancer candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice